Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in …
[HTML][HTML] Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
AJ Sanyal, P Lopez, EJ Lawitz, KJ Lucas, J Loeffler… - Nature Medicine, 2023 - nature.com
The multimodal activities of farnesoid X receptor (FXR) agonists make this class an attractive
option to treat nonalcoholic steatohepatitis. The safety and efficacy of tropifexor, an FXR …
option to treat nonalcoholic steatohepatitis. The safety and efficacy of tropifexor, an FXR …
Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) affects 20–40% of the general population. Despite
significant disease burden and mortality associated with advanced disease, ie, nonalcoholic …
significant disease burden and mortality associated with advanced disease, ie, nonalcoholic …
[HTML][HTML] Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be …
M Yoneda, T Kobayashi, N Wada, T Otani… - … Surgery and Nutrition, 2023 - ncbi.nlm.nih.gov
In a phase 2, multicenter, double-blind, randomized, placebo-controlled trial with a three-
part adaptive design (part A, B, and C), patients diagnosed with NASH and fibrosis stage 2 …
part adaptive design (part A, B, and C), patients diagnosed with NASH and fibrosis stage 2 …
[PDF][PDF] Phase 1 study of EDP‐305, a novel once‐daily oral farsenoid× receptor agonist, in healthy subjects and those with presumptive nonalcoholic fatty liver disease
A Ahmad, K Sanderson, D Dickerson, N Adda - Int J Gastroenterol, 2021 - researchgate.net
Introduction: EDP-305 is a farnesoid X Receptor (FXR) agonist that selectively activates FXR
and is currently under investigation for with the treatment of nonalcoholic steatohepatitis …
and is currently under investigation for with the treatment of nonalcoholic steatohepatitis …
[PDF][PDF] Chronic elevation of plasma fibroblast growth factor 19 in long‐term farnesoid X receptor agonist therapy, a happy marriage or cause for oncological concern?
4) Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek
MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non …
MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non …
[PDF][PDF] Characterization of EDP-305, a highly potent and selective farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis
M Chau, Y Li, M Roqueta-Rivera, K Garlick… - Int J …, 2019 - indigobiosciences.com
Non-alcoholic steatohepatitis (NASH), characterized by hepatocyte injury, inflammation, and
fibrosis, is the main cause of chronic liver disease in the Western world. There are currently …
fibrosis, is the main cause of chronic liver disease in the Western world. There are currently …
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease
that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown …
that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown …
Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists
RA Shah, N Alkhouri, KV Kowdley - Expert Opinion on Emerging …, 2020 - Taylor & Francis
Introduction The discovery of the farnesoid X receptor and its role in bile and lipid
homeostasis has led to the investigation of FXR agonists as a therapy in cholestatic …
homeostasis has led to the investigation of FXR agonists as a therapy in cholestatic …